| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by a clonal expansion of the hematopoietic/progenitor stem cells and an overproduction of blood cells, and mainly consists of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2 mutation positivity in these diseases was 94.4% in PV, 51.9% in ET, and 54.7% in PMF. In the mutant JAK2 negative PV cohort, 2 recurrent SNPs were identified using next generation sequencing based technique targeting whole JAK2 exons. These SNPs are specifically identified in Asians; however, both of the two are silent-mutations. For the diagnostic of PV, detecting the positivity of JAK2 mutations should be considered.
|
